Apr 01, 2020
Salimetrics' Growing List of Cytokines Which Can Be Reliably Tested in Saliva Now Includes IL-17A, IL-5, and IL-7 for Fast, Easy Salivary Biomarker Analysis
Mar 30, 2020
Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Nov 15, 2019
Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study
Oct 17, 2019
Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab
Oct 03, 2019
New Head-to-Head Data Show Taltz® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis
Aug 13, 2019
Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis
Jul 26, 2019
Th17 Inflammatory Pathway Therapeutics Markets, 2022
Jun 14, 2019
Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology
Mar 01, 2019
New Data Affirms Strength of UCB Immuno-Dermatology Portfolio
Dec 17, 2018
Lilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
Oct 23, 2018
Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis Patients
Aug 22, 2018
Nuevolution Discloses the Identity of its "Cytokine X" Program being Interleukin IL-17A and Initiates Promotion of its Small Molecule IL-17A Inhibitor Program Targeting Inflammatory Diseases
Jun 11, 2018
Lilly to Unveil New Data at the Annual European Congress of Rheumatology, Furthering Commitment to Scientific Discovery in Immunology
May 22, 2018
Lilly's Taltz® (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area
Feb 19, 2018
AAD 2018: Treatment with Lilly's Taltz® (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity
Dec 01, 2017
Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis